Compare Cassava Sciences Inc (FLNA) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kimberly Clark Corp — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Kimberly Clark Corp trades at $108.24 (market cap $35.36B). The key difference: Kimberly Clark Corp is far larger — about 665.4× Cassava Sciences Inc's market cap, and Kimberly Clark Corp pays a 4.81% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KMB | |
|---|---|---|
Market Cap | $53.14M | $35.36B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $136.77 |
52-Week Low | $1.09 | $93.05 |
Enterprise Value | -$33.43M | $41.90B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Kimberly-Clark (KMB) trades at $106.82, down 3.05% on the day, near the analyst low target of $106.00. The stock shows a bullish technical signal with RSI at 24.78 indicating potential oversold conditions, while recent quarterly EPS beats and a 4.5% dividend yield highlight fundamental strength. The company's pending Kenvue acquisition and innovation-driven growth strategy are key developments, though revenue declined to $16.45B in 2025 from $20.1B in 2024.
KMB offers a stable income play with consistent dividend payments, but investors face risks from high payout ratios and competitive pressures. Analyst consensus is mixed with 32% buy ratings, suggesting cautious optimism. Near-term performance hinges on Q2 2026 earnings due August 4, 2026, with margins under scrutiny amid input cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
